吴迪;高茜;高超;罗春燕;江杰;刘晓滢;李俊;

• 1:昆明医科大学第一附属医院医学影像科

摘要(Abstract)：

目的 探讨乳腺动态对比增强磁共振成像(dynamic contrast-enhanced magnetic resonance imaging,DCE-MRI)扫描背景实质强化(background parenchymal enhancement,BPE)程度与乳腺癌不同分子亚型间的相关性。材料与方法 回顾性分析2019～2020年在我院行乳腺磁共振检查患者的临床及影像学资料。选择DCE-MRI注射对比剂后第一期图像评价BPE。采用Spearman相关性检验比较BPE程度与临床各因素间的相关性；采用χ2检验比较BPE程度与乳腺癌不同分子亚型间、绝经与否的差异。结果 入组病例199例，包括Luminal A型32例，Luminal B型118例(其中HER-2阳性48例，HER-2阴性70例)，HER-2过表达型24例，基底样型25例。BPE程度与患者年龄、体质量、体质量指数(body mass index,BMI)分层呈负相关(P<0.05);BPE程度与患者身高无显著相关性；BPE程度与患者绝经与否呈正相关(P<0.01)，绝经患者BPE以极少或轻度强化为主，未绝经患者BPE以轻、中度强化为主，部分为重度强化，差异具有统计学意义(P<0.01)。BPE程度与乳腺癌分子亚型存在相关性(P<0.05)，但组间分析结果显示BPE程度在各分子亚型组间差异无统计学意义(P=0.162)；将BPE程度合并后分为极少强化+轻度、中度+重度两组并观察组间差异，结果显示BPE程度在各分子亚型组间差异无统计学意义(P=0.298)。结论 乳腺磁共振BPE程度与患者年龄、体质量、BMI、绝经与否具有相关性，BPE总体与乳腺癌分子亚型存在相关性，但分组后组间差异无统计学意义。

关键词(KeyWords)： 磁共振成像;动态对比增强;乳腺癌;背景实质强化;分子亚型

Abstract:

Keywords:

基金项目(Foundation): 云南省科技计划项目基础研究计划(昆医联合专项，编号：202101AY070001-101);; 云南省高层次卫生健康技术人才培养专项(编号：H-2018007)~~

作者(Authors): 吴迪;高茜;高超;罗春燕;江杰;刘晓滢;李俊;

参考文献(References)：

• [1]Siegel RL,Miller KD,Sauer AG,et al.Colorectal cancer statistics,2020[J].Ca Cancer J Clin,2020,70(1):7-30.DOI:10.3322/caac.21601.
• [2]Breast Cancer Expert Committee of National Cancer Quality Control Center.Quality control index for standardized diagnosis and treatment of breast cancer in China (2022 Edition)[J].Chin J Oncol,2022,44(3):203-208.DOI:10.3760/cma.j.cn112152-20220104-00008.国家肿瘤质控中心乳腺癌专家委员会.中国乳腺癌规范诊疗质量控制指标(2022版)[J].中华肿瘤杂志,2022,44(3):203-208.DOI:10.3760/cma.j.cn112152-20220104-00008.
• [3]Mercado CL.BI-RADS update[J].Radiol Clin North Am,2014,52(3):481-487.DOI:10.1016/j.rcl.2014.02.008.
• [4]Bae SJ,Cha YJ,Na LE,et al.Diagnostic Accuracy of Nonmass Enhancement at Breast MRI in Predicting Tumor Involvement of the Nipple:A Prospective Study in a Single Institution[J].Radiology,2021,301(1):47-56.DOI:10.1148/radiol.2021204136.
• [5]Xiao Q,Gu YJ.Role of imaging in evaluating neoajubant chemotherapy for breast cancer[J].Oncoradiology,2020,29(2):65-72.DOI:10.19732/j.cnki.2096-6210.2020.01.001.肖勤,顾雅佳.影像学在评估乳腺癌新辅助化疗中反应的应用与进展[J].肿瘤影像学,2020,29(2):65-72.DOI:10.19732/j.cnki.2096-6210.2020.01.001.
• [6]You C,Peng WJ,Gu YJ,et al.The diagnostic value of both mammography and MRI in combination with clinical features in high-risk breast lesions[J].Chin J Radiol,2020,54(3):203-208.DOI:10.3760/cma.j.issn.1005-1201.2020.03.006.尤超,彭卫军,顾雅佳,等.乳腺X线摄影及MRI结合临床特征对乳腺高危病变诊断价值[J].中华放射学杂志,2020,54(3):203-208.DOI:10.3760/cma.j.issn.1005-1201.2020.03.006.
• [7]Zhang R,Yang XP.Research progress of background parenchymal.enhancement in breast magnetic resonance imaging[J].Chin J Magn Reson Imaging,2021,12(3):102-104,108.DOI:10.12015/issn.1674-8034.2021.03.025.章蓉,杨晓萍.乳腺磁共振背景实质强化的研究进展[J].磁共振成像,2021,12(3):102-104,108.DOI:10.12015/issn.1674-8034.2021.03.025.
• [8]Onishi N,Li W,Newitt DC,et al.Breast MRI during Neoadjuvant Chemotherapy:Lack of Background Parenchymal Enhancement Suppression and Inferior Treatment Response[J].Radiology,2021,301(2):295-308.DOI:10.1148/radiol.2021203645.
• [9]Vreemann S,Gubern-Mérida A,Borelli C,et al.The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers[J].PLo S One,2018,13(1):e0191399.DOI:10.1371/journal.pone.0191399.
• [10]You C,Gu YJ,Hu XX,et al.The value of background parenchymal enhancement in assessing the molecular subtype of breast cancer[J].Oncoradiology,2020,29(2):79-84.DOI:10.19732/j.cnki.2096-6210.2020.02.003.尤超,顾雅佳,胡晓欣,等.乳腺背景实质强化对乳腺癌分子分型评估的价值[J].肿瘤影像学,2020,29(2):79-84.DOI:10.19732/j.cnki.2096-6210.2020.02.003.
• [11]Ha R,Mango V,Al-Khalili R,et al.Evaluation of association between degree of background parenchymal enhancement on MRI and breast cancer subtype[J].Clin Imaging,2018,51:307-310.DOI:10.1016/j.clinimag.2018.05.008.
• [12]Wu J,Sun X,Wang J,et al.Identifying relations between imaging phenotypes and molecular subtypes of breast cancer:Model discovery and external validation[J].J Magn Reson Imaging,2017,46(4):1017-1027.DOI:10.1002/jmri.25661.
• [13]Devalapalli A,Thomas S,Mazurowski MA,et al.Performance of preoperative breast MRI based on breast cancer molecular subtype[J].Clin Imaging,2020,67:130-135.DOI:10.1016/j.clinimag.2020.05.017.
• [14]Dilorenzo G,Telegrafo M,La Forgia D,et al.Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type[J].Eur J Radiol,2019,113:148-152.DOI:10.1016/j/ejrad.2019.02.018.
• [15]Zhang M,Sadinski M,Haddad D,et al.Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate:Correlation With Breast Cancer Oncotype Dx Score[J].Front Oncol,2021,10:595820.DOI:10.3389/fonc.2020.595820.
• [16]Morris EA,Comstock C,Lee C,et al.BI-RADS:magnetic resonance imaging 2013[M]//D'Orsi CJ,Sickles EA,Mendelson EB,et al.Breast Imaging Reporting and Data System:ACR BI-RADS,breast imaging atlas.Reston:American College of Radiology.2013:29-32.
• [17]Hammond ME,Hayes DF,Dowsett M,et al.American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer[J].J Clin Oncol,2010,28(16):2784-2795.DOI:10.1200/JCO.2009.6529.
• [18]Curigliannno G,Burstein HJ,Winer EP,et al.De-escalating and escalating treatments for early-stage breast cancer:the St.Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017[J].Ann Oncol,2017,28(8):1700-1712.DOI:10.1093/annonc/mdx308.
• [19]Jung Y,Jeong S,Kim JY,et al.Correlations of female hormone levels with background parenchymal enhancement and apparent diffusion coefficient values in premenopausal breast cancer patients:Effects on cancer visibility[J].Eur J Radiol,2020,124:108818.DOI:10.106/j.ejrad.2020.108818.
• [20]Brooks JD,Sung JS,Pike MC,et al.MRI background parenchymal enhancement,breast density and serum hormones in postmenopausal women[J].Int J Cancer,2018,143(4):823-830.DOI:10.1002/ijc.31370.
• [21]Heller SL,Young Lin LL,Melsaether AN,et al.Hormonal Effects on Breast Density,Fibroglandular Tissue,and Background Parenchymal Enhancement[J].Radiographics,2018,38(4):983-996.DOI:10.1148/rg.2018180035.
• [22]Arasu VA,Miglioretti DL,Sprague BL,et al.Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk[J].J Clin Oncol,2019,37(12):954-963.DOI:10.1200/JCO.18.00378.
• [23]Watt GP,Sung J,Morris EA,et al.Association of breast cancer with MRI background parenchymal enhancement:the IMAGINEcase-control study[J].Breast Cancer Res,2020,22(1):138.DOI:10.1186/s13058-020-01375-7.
• [24]Stephen V,Ronco AJ,Elham N,et al.Screening Breast MRI and the Science of Premenopausal Background Parenchymal Enhancement[J].J Breast Imaging,2021,3(4):407-415.DOI:10.1093/jbi/wbab045.
• [25]Chen S,Peng SY,Chen YQ,et al.Research progresses of breast background parenchymal enhancement of MRI[J].J Clin Radiol,2020,39(6):1235-1238.DOI:10.13437/j.cnki.jcr.2020.06.046.陈诗,彭淑怡,陈乐庆,等.乳腺MRI中背景实质强化的研究进展[J].临床放射学杂志,2020,39(6):1235-1238.DOI:10.13437/j.cnki.jcr.2020.06.046.
• [26]Hellgren R,Saracco A,Strand F,et al.The association between breast cancer risk factors and background parenchymal enhancement at dynamic contrast-enhanced breast MRI[J].Acta Radiol,2020,61(12):1600-1607.DOI:10.1177/0284185120911583.
• [27]Jiang C,Zhang SY,Huang YX.Relationship between body mass index and pathological complete remission to neoadju-vant chemotherapy for HER-2 positive breast cancer[J].J Modern Oncol,2020,28(11):1881-1884.DOI:10.3969/j.issn.1672-4992.2020.11.016.姜聪,张世园,黄元夕.体重指数与HER-2阳性乳腺癌新辅助化疗病理完全缓解的关系[J].现代肿瘤医学,2020,28(11):1881-1884.DOI:10.3969/j.issn.1672-4992.2020.11.016.
• [28]Pearson-Stuttard J,Zhou B,Kontis V,et al.Worldwide burden of cancer attributable to diabetes and high body-mass index:a comparative risk assessment[J].Lancet Diabetes Endocrinol,2018,6(2):95-104.DOI:10.1016/S2213-8587(17)30336-2.
• [29]Lee CH,Bryce Y,Zheng J,et al.Outcome of Screening MRI in Premenopausal Women as a Function of the Week of the Menstrual Cycle[J].AJR Am J Roentgenol,2020,214(5):1175-1181.DOI:10.2214/AJR.18.19960.
• [30]Dontchos BN,Rahbar H,Partridge SC,et al.Influence of Menstrual Cycle Timing on Screening Breast MRI Background Parenchymal Enhancement and Diagnostic Performance in Premenopausal Women[J].J Breast Imaging,2019,1(3):205-211.DOI:10.1093/jbi/wbz022.